therapeutics: search

Allos Therapeutics (ALTH) NewsBite - ALTH Upgraded By Wachovia

Allos Therapeutics (ALTH) was upgraded today by analysts at Wachovia and the stock is now at $5.99, up $0.29 (5.09%) on volume of 661,940 shares traded. The brokerage upgraded the stock to "Outperform" from "Market Perform." Over the last 52 weeks the stock has ranged from a low of $3.82 to a high of $10.19. Allos Therapeutics stock has been showing support around $5.36 and resistance in the $6.18 range. Technical indicators for the stock are neutral and S&P does not currently have a STARS rating for ALTH. If you are looking for a hedged play on ALTH the stock seems like it could be a candidate for a December out-of-the-money bull-put credit spread below the 5 range. [ABR-Seven Summits Strategic Investments NewsBite]

InteKrin Therapeutics to Present at the 27th Annual JP Morgan Healthcare Conference on Tuesday, January 13

LOS ALTOS, Calif., Jan 08, 2009 /PRNewswire via COMTEX/ -- InteKrin Therapeutics, Inc., will present at the 27th Annual JP Morgan Global Healthcare Conference at 9:00 a.m. Pacific Time on Tuesday, January 13, 2009, to be held at the Westin St. Francis in San Francisco, California. InteKrin Therapeutics' President and CEO Denny Lanfear will present at the conference.

Intradigm issued new RNAi therapeutics patent

Add our medical news to StumbleUpon - Intradigm issued new RNAi therapeutics patent Add our medical news to Facebook - Intradigm issued new RNAi therapeutics patent

Osiris Therapeutics to Present at 27th Annual J.P. Morgan Healthcare Conference

Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas, announced today that C. Randal Mills, Ph.D., President and CEO, is scheduled to present at the 27

SILENCE THERAPEUTICS PLC - Statement re Patent Decision

Silence Therapeutics' position is strengthened after European Patent Office revokes competitor RNA interference patent in its entirety

Medical News: ImmunoCellular Therapeutics' Cancer Vaccine Demonstrates Immune Response Against Brain Cancer In Clinical Trial

ImmunoCellular Therapeutics' Cancer Vaccine Demonstrates Immune Response Against Brain Cancer In Clinical Trial

InteKrin Therapeutics to Present at the 27th Annual JP Morgan Healthcare Conference on Tuesday, January 13

InteKrin Therapeutics to Present at the 27th Annual JP Morgan Healthcare Conference on Tuesday, January 13

Amicus Therapeutics to Present at J.P. Morgan Healthcare Conference

CRANBURY, N.J., Dec. 22 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD - News) today announced that its President & CEO John F. Crowley will present a corporate overview and the Company's 2009 key business objectives at the 27th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2009, at 11:30 a.m. PT (2:30 p.m. ET). The conference will be held in San Francisco, California.

InteKrin Therapeutics to Present at the 27th Annual JP Morgan Healthcare Conference on Tuesday, January 13

PRNewswire/ -- InteKrin Therapeutics, Inc., will present at the 27th Annual JP Morgan Global Healthcare Conference at

Orexigen Therapeutics Issued a Key Fourth US Patent

SAN DIEGO - Orexigen Therapeutics Inc. announced in a Monday press release that the United States Patent and Trademark Office (USPTO) has issued a patent for what the company refers to as the "Weber/Cowley methods patent" (US Patent No. 7,462,626), which provides coverage for Contrave, the company's lead obesity product candidate now in Phase 3 clinical trials.

Orexigen Therapeutics Issued a Key Fourth U.S. Patent on Contrave

SAN DIEGO, January 05, 2009 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. , a biopharmaceutical company focused on the treatment of obesity, today announced that the United States Patent and Trademark Office (USPTO) has issued a patent for what the Company refers to as the "Weber/Cowley methods patent" (U.S. Patent No. 7,462,626), which provides coverage for Contrave(R), the Company's lead obesity product candidate now in Phase 3 clinical trials.

Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)

PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the United States Patent and Trademark Office (USPTO) has issued a patent for what the Company refers to as the "Weber/Cowley methods patent" (U.S. Patent No. 7,462,626), which provides coverage for Contrave(R), the Company's lead obesity product candidate now in Phase 3 clinical trials.

Intradigm expands RNAi therapeutics patent portfolio

Intradigm, a developer of targeted, systemic RNA interference therapeutics, has received a new US patent that claims methods of enhancing the RNA silencing activity of an RNAi agent through certain structural modifications in various cell types, including mammalian.

Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)

SAN DIEGO, Jan. 5 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (NASDAQ: OREX) , a biopharmaceutical company focused on the treatment of obesity, today announced that the United States Patent and Trademark Office (USPTO) has issued a patent for what the Company refers to as the "Weber/Cowley methods patent" (U.S. Patent No. 7,462,626), which provides coverage for Contrave(R), the Company's lead obesity product candidate now in Phase 3 clinical trials.

Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics

PRNewswire/ -- Intradigm Corporation, a leading developer of targeted, systemic RNA interference (RNAi) therapeutics, today announced the issuance of

Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics

Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics

Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics

Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics

Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics

Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics

New Web Site Links Consumers and Clinicians to Latest Info on Therapeutics

The new Web site, called the Clinician-Consumer Health Advisory Information Network, links clinicians and consumers with therapeutics information to assist in clinical practice and health care decisionmaking.

Bio Nano Consulting Completes Second Major Project for Targanta Therapeutics

LONDON, Dec. 9, 2008--Bio Nano Consulting (BNC), the specialist bionanotechnology product development consultancy, announced at Genesis 2008 in London that it has just completed its second major project for US-based pharmaceutical company, Targanta Therapeutics Corporation. BNC has used its position as world-leaders in cantilever-array assay systems to analyse in greater detail the mechanism of action of Targanta’s lead antibiotic, oritavancin, a novel lipoglycopeptide antibiotic.

Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics

PALO ALTO, Calif., Dec. 2 /PRNewswire/ -- Intradigm Corporation, a leading developer of targeted, systemic RNA interference (RNAi) therapeutics, today announced the issuance of United States patent 7,459,547, entitled "Methods and Compositions for Controlling Efficacy of RNA Silencing." The issued patent, which is based on the seminal research of Philip Zamore, Ph.D., the Gretchen Stone Cook Chair of Biomedical Sciences and Professor of Biochemistry & Molecular Pharmacology at

Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency...

Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics Zamore Patent Covers Methods for Enhancing RNAi Structural Features and Strengthens Intradigm's Competitive Position PALO ALTO, Calif., Dec. 2 /PRNewswire/ -- Intradigm Corporation, a leading developer of targeted, systemic RNA interference (RNAi) therapeutics, today announced the issuance of United States patent 7,459,547, entitled "Methods and Compositions for Controlling Efficacy of RNA Silencing." The issued patent, which is based on the seminal research of Philip Zamore, Ph.D., the Gretchen Stone Cook Chair of Biomedical Sciences and Professor of Biochemistry & Molecular Pharmacology at University of Massachusetts Medical School, generally claims methods of enhancing the RNA silencing activity of an RNAi agent through certain str

Natura Therapeutics Receives Patent For Dietary Supplement Designed To Boost Stem Cells

TMC Launches New Sites :: Cable | 4G Wireless Evolution | Satellite | Green Tech | IT | IVR | ITEXPO East begins in: REGISTER NOW!

Celgene Cellular Therapeutics: Regenerative Growth

By selling his company to a large corporation, Dr. Robert Hariri was able to watch his dream of turning stem cells into medicine become a reality.

Search took 0.01 seconds.